Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole

AIDS
M D Edge, D Rimland

Abstract

To evaluate the effect of the type of Pneumocystis carinii pneumonia (PCP) prophylaxis on the development of community-acquired bacteremia. Case-control study using all cases of community-acquired bacteremia identified prospectively during a longitudinal study of all infections in a cohort of HIV-infected persons. University-affiliated Department of Veterans Affairs Medical Center HIV program. All patients with community-acquired bacteremia seen at the facility between January 1990 and December 1995 were included. Controls, seen at the same facility and matched by date and CD4 count, were used to assess risk factors. A total of 57 cases and 114 controls were analysed. Risk of development of bacteremia, distribution of organisms, and effect of specific prophylactic regimens for PCP. Bacteremia was caused by Staphylococcus aureus (23%), Pseudomonas aeruginosa (18%), Escherichia coli (16%), Streptococcus pneumoniae (14%) and others (31%). Groups were similar by age, race, HIV risk factors and CD4 count. The presence of an intravenous catheter was mildly predictive of the development of bacteremia [odds ratio (OR), 2.67; P = 0.024]. Type of PCP prophylaxis in cases and controls with CD4 < 200 x 10(6)/l included co-trimoxazole (trim...Continue Reading

Citations

Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rachel J GordonFranklin D Lowy
Jun 8, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rakhi KohliUNKNOWN HER Study Group
Jun 1, 1997·AIDS Patient Care and STDs·R M Rutstein, S E Starr
Oct 1, 1997·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·E N Janoff, J B Rubins
Feb 9, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marta Bodro, David L Paterson
Apr 20, 2002·Current Opinion in Infectious Diseases·K Grimwade, C Gilks
Feb 29, 2000·The Pediatric Infectious Disease Journal·C RongkavilitC D Mitchell
Feb 12, 1999·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·S E BuskinS G Hopkins
Aug 24, 1999·Current Opinion in Clinical Nutrition and Metabolic Care·W Dröge
Mar 11, 2000·Current Opinion in Clinical Nutrition and Metabolic Care·W Dröge, R Breitkreutz
Apr 12, 2006·Current Opinion in Clinical Nutrition and Metabolic Care·Wulf Dröge
May 6, 2005·Paediatric Drugs·Shamez Ladhani, Mehdi Garbash
Sep 21, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michaëla A M HusonMartin P Grobusch
Mar 8, 2016·Virulence·Lucia TaramassoAntonio Di Biagio
Mar 25, 2014·Seminars in Pediatric Neurology·Macpherson Mallewa, Jo M Wilmshurst
Jun 29, 2004·The Lancet Infectious Diseases·Daniel R FeikinEdward N Janoff
Oct 11, 2005·HIV Clinical Trials·Vijayalakshmi Nagappan, Powel Kazanjian
Dec 29, 2000·Journal of Chemotherapy·R ManfrediF Chiodo
May 2, 2001·Journal of Chemotherapy·R ManfrediF Chiodo
Apr 2, 2019·Scientific Reports·L TaramassoA Di Biagio
Dec 11, 2019·Transactions of the Royal Society of Tropical Medicine and Hygiene·Deng B MadutJohn A Crump
Nov 4, 2005·Medicina clínica·Natividad Benito HernándezJosé María Gatell Artigas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.